Top Markets
Coin of the day
Solasia Pharma K.K. Solasia Pharma K.K.

Solasia Pharma K.K.

4597
Rankning i aktier #24757
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Aktiekurs
$0.20877985
Marknadsvärde
$57.00M
Förändring (1 dag)
-11.11%
Förändring (1 år)
-20.59%
Land
JP
Handel Solasia Pharma K.K. (4597)

Kategori

P/B-tal för Solasia Pharma K.K. (4597)
P/B-tal per 2026 TTM: 0
Enligt Solasia Pharma K.K. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för Solasia Pharma K.K. från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter